Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Blinatumomab as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia (ALL)

Trial Profile

Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Blinatumomab as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia (ALL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Blinatumomab (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Mesna; Methotrexate; Ofatumumab; Pegfilgrastim; Prednisone; Rituximab; Vincristine
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Nov 2016 Status changed from not yet recruiting to recruiting.
    • 09 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top